Ather Energy
March 10, 2017
March 10, 2017

Mitra Biotech

Mitra Biotech’s patented technology platform, Canscript, helps hospitals and doctors figure the right combination and sequence of drugs to be administered to cancer patients. Canscript analyses biopsy samples to arrive at specific combinations of drugs and the treatment to be given to specific patients. Canscript measures a number of functional parameters including cell viability, proliferation, death and morphology.

Canscript needs about a week to test samples and classify various drug combinations as potential responders and non-responders, enabling physicians to take informed decisions on the treatment to administer. Mitra Biotech was established in 2008 as a US company. It moved from Boston to Bengaluru the following year to validate its technology platform. Canscript has been validated for eight different cancer types on 2,000 patients.

Comments are closed.